Real-world long-term effectiveness of ustekinumab in Crohn's disease: results from the ENEIDA registry-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Real-world long-term effectiveness of ustekinumab in Crohn's disease: results from the ENEIDA registry

Published:2020-08-08 Issue: Volume: Page:
ISSN:0269-2813
Container-title:Alimentary Pharmacology & Therapeutics
language:en
Short-container-title:Aliment Pharmacol Ther

Author:

Iborra Marisa¹^ORCID,Beltrán Belén¹,Fernández-Clotet Agnes²,Iglesias-Flores Eva³,Navarro Pablo¹,Rivero Montserrat⁴,Gutiérrez Ana⁵,Sierra-Ausin Mónica⁶,Mesonero Francisco⁷,Ferreiro-Iglesias Rocío⁸,Hinojosa Joaquín¹^ORCID,Calvet Xavier²,Sicilia Beatriz⁹,González-Muñoza Carlos²,Antolín Beatriz¹⁰,González-Vivo María²,Carbajo Ana Y.¹⁰,García-López Santiago¹¹,Martín-Cardona Albert²^ORCID,Surís Gerard²,Martin-Arranz María Dolores⁷,de Francisco Ruth¹²,Cañete Fiorella²,Domènech Eugeni²^ORCID,Nos Pilar¹,

Affiliation:

1. Valencia Spain

2. Barcelona Spain

3. Córdoba Spain

4. Santander Spain

5. Alicante Spain

6. León Spain

7. Madrid Spain

8. Santiago de Compostela Spain

9. Burgos Spain

10. Valladolid Spain

11. Zaragoza Spain

12. Asturias Spain

Publisher

Wiley

Subject

Pharmacology (medical),Gastroenterology,Hepatology

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1111/apt.15958/fullpdf

Reference26 articles.

1. Ustekinumab in Crohn's disease: evidence to date and place in therapy;Engel;Ther Adv Chronic Dis,2016

2. Ustekinumab in treatment of Crohn's disease: design, development, and potential place in therapy;Deepak;Drug Des Devel Ther,2016

3. Profile of ustekinumab and its potential in patients with moderate-to-severe Crohn's disease;Tuskey;Clin Exp Gastroenterol,2014

4. The innate and adaptive immune system as targets for biologic therapies in inflammatory bowel disease;Holleran;Int J Mol Sci,2017

5. Discovery and mechanism of ustekinumab: a human monoclonal antibody targeting interleukin-12 and interleukin-23 for treatment of immune-mediated disorders;Benson;MAbs,2011

Cited by 44 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. One-year Safety and Effectiveness of Ustekinumab in Patients With Crohn’s Disease: The K-STAR Study;Inflammatory Bowel Diseases;2024-08-03

2. Approach to loss of response to advanced therapies in inflammatory bowel disease;World Journal of Gastroenterology;2024-06-14

3. Comparative effectiveness and safety of ustekinumab at different intervals of maintenance phase in inflammatory bowel disease: a systematic review and meta-analysis;European Journal of Gastroenterology & Hepatology;2024-02-16

4. Beyond the Gut: A Systematic Review and Meta-analysis of Advanced Therapies for Inflammatory Bowel Disease-associated Extraintestinal Manifestations;Journal of Crohn's and Colitis;2024-01-08

5. Controversies in the management of anti-TNF therapy in patients with Crohn’s disease: a Delphi consensus;BMJ Open Gastroenterology;2024-01

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3